Our CEO, Liz Parrish was invited at this event for a keynote interview with Charles Goddard, the editorial director for The Economist Asia Pacific Intelligence Unit. They discussed the complexity of regulations, the extraordinarily long time it takes for drug development from bench to bedside, the current funding environment surrounding biotech, and the pace of medical innovations. During the keynote, Liz emphasized that BioViva’s main aim is to make advanced gene and cell therapies available to all patients in need. To further this cause BioViva supports innovative and adaptive clinical trials, new models for preclinical testing, and accelerating the time to develop advanced gene and cell therapy. Finally, Liz highlighted the importance of testing gene and cell therapy in humans as quickly as possible, because animal models are not accurate.
Comments are closed.